文献速递肝病消化道出血

达比加群对门静脉血栓再通率、疾病进展及生存期的经验

Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-03

研究评估达比加群治疗非肿瘤性急性及慢加急性门静脉血栓的临床、促凝及遗传风险因素与结局。119例患者接受达比加群,中位随访32个月再通率47.1%,高于未抗凝组自发性再通率21.4%(p=0.005),VKA组无再通。高FVIII:Ag为非再通预测因素,达比加群在Child-Pugh A/B级肝硬化中安全,CP-C级需进一步研究。

要点

  • 达比加群组总体再通率47.1%,未抗凝组自发性再通率21.4%(p=0.005),VKA组无再通。
  • 多变量分析显示FVIII:Ag水平(HR 0.6)、非闭塞性PVT(HR 3.5)和急性PVT(HR 2.1)为再通预测因素。
  • 达比加群在Child-Pugh A和B级肝硬化中安全,CP-C级需进一步研究。

核心结论

  • 达比加群治疗119例门静脉血栓患者,32个月随访中47%实现再通,高于未治疗队列的自发性再通率21.4%。
  • 高FVIII:Ag水平是非再通的预测因素。
  • 达比加群在Child-Pugh A和B级肝硬化中安全,在CP-C级需进一步研究。

研究设计与样本

  • 研究纳入2021年1月至2024年1月新诊断的非肿瘤性急性及慢加急性门静脉血栓患者(年龄≥18岁),无肝硬化或肝硬化Child-Pugh A/B/C≤10分者开始达比加群治疗并随访。
  • 达比加群组119例,对照组包括28例拒绝抗凝或无法随访者及6例CP-C级接受VKA者。

主要发现

  • 达比加群组PVT类型1为61例(51.3%)、类型2为34例(28.6%)、类型3为24例(20.2%);肝硬化72例(60.5%),其中CP-A 27例(37.5%)、CP-B 43例(59.7%)、CP-C 2例(2.8%)。
  • 促凝因素包括JAK2V617F突变(10.1%)、CALR突变(2.5%)、因子V Leiden突变(1.6%)、抗磷脂综合征(15.2%)、孤立性蛋白C缺乏(14.3%)和蛋白S缺乏(16.8%)。
  • 达比加群组总体再通率56例(47.1%),其中完全再通25例(21%)、部分再通31例(26%)、PVT稳定63例(52.9%),中位随访32个月。
  • 未抗凝组自发性再通率21.4%(28例;与达比加群组相比p=0.005),VKA组无再通。
  • 多变量分析显示再通预测因素为FVIII:Ag水平(HR 0.6;95%CI 0.3-0.9,p=0.032)、非闭塞性PVT(HR 3.5;95%CI 1.9-5.6,p=0.025)和急性PVT(HR 2.1;95%CI 1.5-3.2,p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran-treated patients with non-tumoural acute and acute-on-chronic portal vein thrombosis (PVT). METHODS: Patients with a new diagnosis of non-tumoural acute and acute-on-chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child-Pugh (CP)-A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals. RESULTS: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.3%), type 2 (34, 28.6%), type 3 (24, 20.2%); 72 (60.5%) with cirrhosis [CP-A (27, 37.5%), CP-B (43, 59.7%) and CP-C10 (2, 2.8%)]. Procoagulant factors noted were JAK2V617F (10.1%), CALR (2.5%) and factor V Leiden (1.6%) mutations, antiphospholipid syndrome (APS, 15.2%), isolated Protein C (14.3%) and Protein S (16.8%) deficiency. COMPARATORS: 28 patients who declined anticoagulation/were unable to come for follow-up, and six with CP-C received VKA. Overall recanalization rate (RR) on dabigatran was 56 (47.1%); 25 (21%) complete recanalization, 31 (26%) partial recanalization and 63 (52.9%) stable PVT over median follow-up of 32 months. Patients not anticoagulated had a spontaneous RR in 21.4% (28 patients; p = 0.005 compared with dabigatran group) and none recanalized on VKA. On multivariable analysis, predictors of recanalization on dabigatran were Factor VIII Antigen level (FVIII:Ag, HR 0.6; 95% CI 0.3-0.9, p = 0.032), non-occlusive PVT (HR 3.5, 95% CI 1.9-5.6, p = 0.025) and acute PVT (HR 2.1; 95% CI 1.5-3.2, p = 0.003). Mortality was 14 (11.8%). CONCLUSION: On dabigatran, 47% of 119 patients achieved portal vein recanalization over 32 months of follow-up which was higher than the spontaneous RR (21.4%) in an untreated cohort. High Factor VIII:Ag was a predictor of non-recanalization. Dabigatran was safe in cirrhosis (CP-A and B) while further work is needed in CP-C.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Premkumar M, Bhujade H, Sharma P, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025. PMID: 39748673. doi:10.1111/apt.18474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。